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Neural electrodes are designed to interface with the nervous system and
provide control signals for neural prostheses. However, robust and reliable
chronic recording and stimulation remains a challenge for neural electrodes.
Here, a novel method for the fabrication of soft, low impedance, high charge
density, and controlled releasing nanobiomaterials that can be used for the
surface modification of neural microelectrodes to stabilize the electrode/
tissue interface is reported. The fabrication process includes electrospinning
of anti-inflammatory drug-incorporated biodegradable nanofibers,
encapsulation of these nanofibers by an alginate hydrogel layer, followed by
electrochemical polymerization of conducting polymers around the
electrospun drug-loaded nanofibers to form nanotubes and within the
alginate hydrogel scaffold to form cloud-like nanostructures. The three-
dimensional conducting polymer nanostructures significantly decrease the
electrode impedance and increase the charge capacity density.
Dexamethasone release profiles show that the alginate hydrogel coating
slows down the release of the drug, significantly reducing the burst effect.
These multifunctional materials are expected to be of interest for a variety of
electrode/tissue interfaces in biomedical devices.1. Introduction
Recording and stimulating neural prostheses can improve our
understanding of the organization and operation of the nervous
system and may lead to improved prosthetic devices for tackling
of some mankind’s most debilitating disorders, including
deafness, paralysis, blindness, epilepsy, and Parkinson’s disease.
Neural microelectrodes, such as microwires[1] and microfabri-
cated silicon electrodes,[2–4] are capable of interfacing with the
central and peripheral nervous system at the cellular level by
transducing ionic biological signals to electronic signals.[5] A low
impedance electrode/tissue interface is critically important to
maintain signal quality for recording, as well as effective charge
transfer for stimulation. However, neural microelectrodes often
exhibit high initial electrode impedance because of their small[*] Dr. M. R. Abidian
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tion processes from the reactive cellular
response progressively increase the impe-
dance of electrode/tissue interface over the
long term.[8–11]
Several studies have been conducted to
explore strategies to reduce the initial
impedance of electrode sites or to limit
early and late reactive responses near the
electrode/tissue interface. These strategies
include: i) optimizing the size,[10]
shape,[8,12] tip geometry,[10] texture,[10,13]
material substrate,[13–15] and insertion
procedures[10,12,16,17] to minimize the
initial trauma to the brain tissue during
implantation; ii) deposition of metals[18]
and metal oxides[19] on the surface of
electrode sites and applying bias voltage
pulses[20] to decrease the initial impedance
of the electrode; iii) bioactive coatings on
the electrode using biomolecules,[21,22] and
the systemic or local delivery of anti-
inflammatory drugs[23,24] to reduce the
reactive tissue response and encapsulation
process.
Recently, conducting polymers such as poly(pyrrole) (PPy) and
poly(3,4-ethylenedioxythiophene) (PEDOT) have been considered
for biomedical applications because of their physical, electrical,
and biocompatibility characteristics.[25,26] Since, their responses
to electrochemical or electronic signals can produce a change in
conductivity and volume, conducting polymers are of interest for
neural engineering applications such as neuronal cell signal-
ing,[27] neural interface,[28,29,30] and controlled drug delivery.[31,32]
We have successfully demonstrated that PPy and PEDOT can be
electrochemically polymerized on neural microelectrode sites in
the form of films,[33] interconnected microcavities,[34] micro-
fibrils,[35] and nanotubes (NTs).[31] These morphologies signifi-
cantly increase the effective surface area of the electrode/tissue
interface. As a result, the capacitance of the electrode site
dramatically increases, creating a corresponding reduction in
electrode site impedance.[30] PEDOT exhibits higher conductivity
and chemical stability than PPy in the oxidized state.[36–41] We
have demonstrated that PEDOT can be polymerized on neural
electrodes and around electrospun nanofibers to form PEDOT
nanotubes[30] (PEDOT NTs), and that these nanotubes can be
used for the controlled release of anti-inflammatory drugs.[31]
Previous studies have described the importance of considering
the dramatic differences in mechanical and electrical properties
between an implanted microelectrode and the ionically active
neural tissue.[9,13,28] Hydrogels provide a soft mechanical buffer
layer, but they move the electrode away from the target cells, and











Figure 1. Schematic diagram of the fabrication process for multifunctional
polymer coatings on the neural microelectrodes: A) uncoated microelec-
trode, B) electrospinning of DEX-loaded biodegradable nanofibers,
C) alginate hydrogel coating, D) electrochemical polymerization of PEDOT
on the electrode sites, around the DEX-loaded electrospun biodegradable
nanofibers, and within the hydrogel scaffold.
574coatings can significantly reduce electrode impedance, but they
are relatively thin (5mm) and only provide a modest mechanical
buffer effect. Drugs such as dexamethasone (DEX) can be
incorporated into biodegradable matrices, but these polymers are
insulators and would prevent the electrodes from functioning
properly if used in a simple continuous coating. It is therefore of
interest to find techniques that could create surfaces that are
simultaneously mechanically soft, low impedance, and able to
release drugs in a controlled fashion.
In this study, we describe the design and characterization of a
multifunctional, hybrid nanostructured interface for neural
microelectrodes that is soft, low impedance, has high charge
density, and is capable of controlled drug release. Our design
includes: i) biodegradable electrospun nanofibers for the
controlled release of drugs and to provide a scaffold for the
formation of conducting polymer nanotubes and ii) hydrogel
layers for the sustained release of drugs, and to provide a scaffold
for formation of nanostructured cloud-like conducting polymer.
These hydrogel coatings provide a mechanical buffer layer
between the hard silicon-based probe and the soft brain tissue, a
scaffold for growing the conducting polymer within the hydrogel
matrix, and a diffusion barrier for controlling drug release. Since
high electrical conductivity is one of the most important
parameters for achieving stable communication with neurons,
and the electrospun polymer layer used in this experiment was an
electrically nonconductive material, it was necessary to enhance
the conductivity of the nanofibers using conducting polymers. In
order to enhance the electrical properties of the electrode sites,
PEDOTwas electrochemically polymerized on the electrode sites,
around the nanofibers and eventually inside the alginate hydrogel
matrix. Figure 1 shows the fabrication process that includes
electrospinning of drug-loaded biodegradable nanofibers
(Fig. 1B), hydrogel coating of the neural electrode using a
dipping method (Fig. 1C), and finally electrochemical polymer-
ization of conducting polymer around the electrospun nanofibers
within the hydrogel scaffold (Fig. 1D). We believe that the
hydrogel layer stabilizes the release of DEX due to hydrolytic
degradation of the electrospun fibers. This controlled release
should reduce the risk of exposure to high systemic doses of DEX
that are associated with serious side effects such as diabetes,
hemorrhagic ulcer, skin atrophy, and osteoporosis.[42,43]2. Results and Discussion
2.1. Electrospinning of Dexamethasone-Loaded Nanofibers on
the Neural Electrode
Among bioresorbable polymers, poly(a-hydroxy acids) such as
poly(L-lactic acid) (PLLA) and poly(lactic-co-glycolic acid) (PLGA)
have been extensively used as drug carriers[44–46] and scaffolds for
tissue engineering[47–49] because of their tailorable biodegrad-
ability and good biocompatibility.[50] These polymers degrade into
nontoxic products and have received United States Food and
Drug Administration approval for medical devices.[51] As shown
in Figure 2B–D, DEX-incorporated electrospun nanofibers
were prepared and collected on the neural microelectrodes.
Figure 3 shows scanning electron micrographs (SEM) of DEX- 2009 WILEY-VCH Verlag GmbH &loaded poly(L, D-lactic-co-glycolic acid) with composition ratio of
LA/GA 75:25 (PLDL75G25A)/DEX (ratio 10:1), poly(L, D-lactic
acid) (PLDLA)/DEX (ratio 10:1), and PLLA/DEX (ratio 4:1). PLLA
has higher molecular weight than PLDL75G25A and PLDLA,
therefore, the solubility of PLLA in chloroform is less than
PLDL75G25A and PLDLA. DEX was completely dissolved in the
chloroform with the concentration of 15.6mg mL1 for PLLA/
DEX solution (ratio 4:1) and 22.5mg mL1 for PLDL75G25A/
DEX, and PLDLA/DEX solution (ratio 10:1), which is in the range
of maximum solubility of DEX in chloroform (maximum
concentration of 25mg mL1). The diameters of the DEX-loaded
nanofibers ranged from 40 to 150 nm with the majority between
55 and 96 nm (Fig. 3). In contrast to PLDLA/DEX and
PLDL75G25A/DEX, the surface texture of the PLLA/DEX fibers
had a well-defined porousmorphology (Fig. 3E and F).[31,52] Since,
PLDLA and PLDL75G25A are amorphous polymers and did not
exhibit this porous surface morphology when processed from the
same solvent, it may be that the crystallization of PLLA caused











Figure 2. Optical micrographs of A) silicon-based eight-channel recording gold sites with surface
area of 1 250mm2, B) top view of electrospun DEX-loaded biodegradable nanofibers on the
surface of silicon electrode, C) higher magnification of (B) showing single gold site and random
distribution of nanofibers on the surface of neural electrode, D) side view of (B) showing the
thickness of nanofibers on the neural electrode.
Figure 3. SEMs of DEX-loaded electrospun: A) and B) PLDL75G25A nanofibers (PLDL75G25A/DE
10:1), E) and F) PLLA nanofibers (PLLA/DEX, 4:1). DEX was completely dissolved in the chloroform
solution and 22.5mg mL1 for PLDL75G25A/DEX and PLDLA/DEX solution which is in the r
concentration of 25mg mL1). The diameters of the DEX-loaded nanofibers ranged from 40 to 1
Adv. Funct. Mater. 2009, 19, 573–585  2009 WILEY-VCH Verlag GmbH & Co. KGaA,Figure 2, the nanofibers were distributed
randomly in a mat on the surface of the probe
and covered the entire shank of the neural
probe. The thickness of the resulting fiber mat
was 24 8mm on each side of electrode for
1min of electrospinning with the DEX-poly-
mer solution.
When the concentration of DEX in the
solutions was increased beyond the solubility
limit (25mg mL1), the excess DEX particles
aggregated together and were covered by layers
of polymers along the fiber strings (Fig. 4). The
size of the vesicles containing the DEX
particles was in the range of 5–20mm.
Figure 4 shows SEM images overloaded DEX
in PLDLA (PLDA/DEX, 8:1), PLDL75G25A
(PLDL75G25A/DEX, 8:1), and PLLA (PLLA/
DEX, 2:1) with DEX concentration of 33.2,
33.2, and 31.2mg mL1 in chloroform,
respectively.2.2. Alginate Coating of the Neural
Electrode
After electrospinning the drug-loaded biode-
gradable polymer nanofibers (PLDL75G25A/X, 10:1), C) and D) PLDLA nanofibers (PLDLA/DEX,
with the concentration of 15.6mgmL1 for PLLA/DEX
ange of solubility of DEX in chloroform (maximum












Figure 4. SEM of DEX-loaded electrospun A) and B): PLDL75G25A nanofibers (PLDL75G25A/DEX, 8:1); C) and D): PLDLA nanofibers (PLDLA/DEX, 8:1);
E) and F): PLLA nanofibers (PLLA/DEX, 2:1). DEX was dissolved in the chloroform at a concentration of 31.2mgmL1 for PLLA/DEX solution and 33.2mg
mL1 for PLDL75G25A/DEX and PLDLA/DEX solution which is beyond the range of solubility of DEX in chloroform (maximum concentration of 25mg
mL1). The size of the vesicles containing the DEX particles was in the range of 5–20mm. The excess DEX particles aggregated together and were covered
by layers of polymers along the fiber strings.
576DEX), alginate was ionically crosslinked by Ca2þ ions using a dip
coating method which covered the entire shank of neural
microelectrodes. The thickness of hydrogel coating depends on
the concentration of alginate polymer, Ca2þ ions in the solutions,
as well as the number of dipping cycles. It was found that the
lateral movement of the neural electrode and speed of dipping
effects on the uniformity of the alginate coating around the shank
of the probe. Figure 5A–C shows optical micrographs of the top
and side views of alginate hydrogels in hydrated state that covered
the entire shank of the neural probe. The overall thickness of
hydrogel was 360 23mm in hydrated condition after 4 dipping
cycles in 1% w/w alginate and 0.5 M CaCl2 solutions. However,
this thickness decreased to 60 5mm in dehydrated (dried)
situation, which is the total thickness of DEX-loaded PLDL75G25
nanofibers on both sides of the neural probe (Fig. 5D–F). To
minimize the amount of damage during the implantation,[9]
coated neural electrodes should be inserted into the brain in the
dehydrated state. Once the electrode is placed in the tissue, it will
rehydrate from water naturally available in the tissue.[53] It is
therefore necessary to have conducting pathways through the gel
so that it is possible to maintain communication with the cells
that might be pushed from the electrode when the gel re-swells.
Figure 5G and H shows SEM images of dehydrated alginate on
the surface of a neural electrode that shows the electrospun
nanofibers underneath the dried alginate membrane. 2009 WILEY-VCH Verlag GmbH &2.3. Electrochemical Polymerization of PEDOT in Hydrogel
Scaffolds
PEDOTwas electropolymerized on the 1 250-mm2 gold electrode
sites that were coated by DEX-loaded PLDL75G25A electrospun
nanofibers and alginate hydrogel. The total applied charge density
during electrochemical deposition was 2.88C cm2 which caused
theminimum impedance[30,31] (applied current 20 nA for 1800 s).
Figure 6A shows top view of the deposited PEDOT on the
electrode site (black color). The side view optical microscope
image (Fig. 6B) revealed that PEDOT was grown vertically from
the conductive site, around the electrospun nanofibers,[31] and
gradually expanded throughout the hydrogel structure with a
cloud-like morphology. Visual inspection showed that as
electropolymerization time increased, PEDOT content also
increased. For electrochemical polymerizations longer than
30min, the black PEDOT phase had vertically permeated up to
the surface of hydrogel. The PEDOT grows around the filaments
of the alginate gel, preserving the open structure and pathways for
transport through the aqueous phase.[54] Figure 6C and D shows
SEM images of PEDOT NTs that were left on the electrode site
after dissolving away the alginate coating in deionized water and
PLDL75G25A nanofibers in chloroform. These images show the
formation of PEDOT around the DEX-loaded PLDL7525GA











Figure 5. Optical micrographs of A) top view of neural electrode after coating with DEX-loaded electrospun nanofibers and alginate hydrogel in hydrated
state, B) side view of (A) which shows entire electrode, C) side view of (A) which is higher magnification of (B), D) top view of neural electrode after coating
with DEX-loaded electrospun nanofibers and alginate hydrogel in dehydrated state, E) side view of (D) which shows entire electrode after dehydration of
alginate, F) side view of (D) which is higher magnification of in dehydration of alginate (E), G) highermagnification of (F) which shows thickness of alginate
hydrogel after dehydration and electrospun nanofibers inside of hydrogel on top of electrode, H) false-colored SEM images of neural electrode after coating
with DEX-loaded electrospun nanofibers and alginate hydrogel in dehydrated state of alginate, I) false-colored higher magnification of (H).2.4. Electrochemical Impedance Spectroscopy (EIS)
EIS was used to explore the conductivity of the polymer coatings
over a frequency range 1–105 Hz for PEDOT NTs, cloudy PEDOT
inside the alginate hydrogel (HGþPEDOT), and PEDOT
deposition around the electrospun nanofibers, and within the
alginate hydrogel (PEDOT NTsþHGþPEDOT) (Fig. 7G). The
impedances at 1 kHz are particularly important because they
correspond to the characteristic frequency of neuronal action
potentials.[55] Figure 7G shows EIS of the electrode site and the
change in impedance as a function of different coatings. The
electrode’s impedance across all frequencies was moderately
increased by the layer of nonconductive DEX-loaded
PLDL75G25A nanofibers (Fig. 7B; PLGA NFs). This impedance
increased slightly after coating with conductive hydrogel (Fig. 7C;
PLGA NFsþHG). After PEDOT deposition around the DEX-
loaded PLGA nanofibers and within the alginate hydrogel (Fig.
7F; PEDOT NTsþHGþPEDOT), the impedance at 1 kHzAdv. Funct. Mater. 2009, 19, 573–585  2009 WILEY-VCH Verldecreased by about two orders ofmagnitude from the unmodified
electrode. We also compared the impedance of PEDOT
NTsþHGþPEDOT with PEDOT NTs (Fig. 7E; PEDOT NTs
without alginate hydrogel) and cloudy PEDOT (Fig. 7D;
HGþPEDOT without PEDOT NTs). As shown in Figure 7G,
the impedance of PEDOT NTsþHGþPEDOT is less than the
PEDOT NTs, which are in turn less than HGþPEDOT. Although
the impedance of PEDOT NTs (10.7 2.3 kV at 1 kHz) was
less than cloudy PEDOT (33.1 4.1 kV at 1 kHz), the effective
surface area was increased by a combination of PEDOT NTs on
the surface of electrode sites as well as cloudy PEDOT inside the
alginate (PEDOT NTsþHGþPEDOT), which produced the
minimum impedance. Table 1 shows the impedance value at
1 kHz for different coatings. The initial impedance of the bare
gold sites was 783 15.7 kV, which decreased to a minimum of
2.50.5 kV after PEDOT deposition around electrospun
nanofibers and within the hydrogel matrix (PEDOT NTsþ
HGþPEDOT). This dramatic change is presumably due to











Figure 6. A) Optical micrograph of deposited PEDOT (black color) on electrode site (top view), B) side view of (A) showing vertical growth of PEDOT from
an electrode site and through the alginate hydrogel scaffold (black color), C) SEM images of electrode site after dissolving the alginate coating and
electrospun nanofibers. This image reveals that PEDOTwas grown around the electrospun nanofibers to form PEDOTNTs. D) Highermagnification image
of (C).
578Ludwig et al. reported chronic neural recording usingmodified
microelectrodes with PEDOT.[56] Surfactant-templated PEDOT
was deposited on 703-mm2 electrode sites and reduced
impedance of electrode sites from 900 to 60 kV. Their results
showed that the quality of signal recording in rats was
improved.[56] Since cloudy PEDOT in hydrogel in combination
with nanotubes (PEDOT NTsþHGþPEDOT) has an even lower
impedance, our EIS measurements suggest that even higher
quality signals should be recorded if these materials were used in
vivo. By testing the impedance of neighboring sites that were
200-mm apart, we found that the cloud-like PEDOT did not
connect the electrode sites together.2.5. Cyclic Voltammetry (CV)
CV was used to explore the charge capacity per unit area (charge
capacity density or CCD) through the electrode sites after surface
modification with PEDOT NTs, cloudy PEDOT inside hydrogel
(HGþPEDOT), and PEDOT NTs in combination with cloudy
PEDOT inside the hydrogel (PEDOT NTsþHGþPEDOT). The 2009 WILEY-VCH Verlag GmbH &electrode sites were swept from 0.9–0.5 V at a scan rate of
100mVs–1 versus Ag/AgCl reference electrode. During oxidation
or reduction of PEDOT, the polymer undergoes expansion or
contraction, which is associated with migration of counter ions
(doping) and cations either toward the solution or toward the
PEDOT (depending on the size of the counter ions).[26] The
oxidation and reduction reactions involve current flow through
PEDOT that appears as peaks (Ipc and Epc, corresponding to
cathodic reduction current and potential, Ipa and Epa corre-
sponding to anodic oxidation current and potential). Although
PEDOT electropolymerization was done at the same applied
charge density 2.88C cm2, the absolute value of current peaks
(jIpcj and jIpaj) varies in the following order: PEDOT
NTsþHGþPEDOT>PEDOT NTs>HGþPEDOT (Fig. 7H).
We also observed slight changes in oxidation and reduction
potential for different coatings that have been recorded and
described through literature for PEDOT derivatives.[37,38] The
surface area under the CV curve is proportional to the CCD that a
particular coating material can transfer (store) during one cycle of
CV. The CCD is calculated by dividing the product of the voltage
and the time (pulse width) by the product of the impedance and











Figure 7. Schematic illustration of A) uncoated electrodes, B) DEX-loaded electrospun PLDL75G25A nanofibers on the electrodes (PLGANFs), C) alginate
hydrogel coating of DEX-loaded electrospun PLDL75G25A nanofibers on the electrodes (HGþPLGA NFs), D) cloudy PEDOT inside the alginate hydrogel
on particular electrodes (HGþ PEDOT), E) PEDOT NTs on the electrodes (PEDOT NTs), F) PEDOT NTs and cloudy PEDOT inside the hydrogel on the
electrodes (PEDOT NTsþHGþPEDOT), G) EIS of bare gold (black squares), PLGA NFs (green hollow triangles), PLGA NFsþHG (orange circles),
HGþ PEDOT (red hollow circles), PEDOT NTs (blue triangles), and PEDOT NTsþHGþ PEDOT (pink stars), with the applied deposition charge density
was 2.88 C cm2, H) CV of bare gold (black squares), HGþPEDOT (red hollow circles), PEDOT NTs (blue triangles), and PEDOT NTsþHGþ PEDOT
(purple stars); the potential was swept from 0.9 to 0.5 V at a scan rate of 100mV s1.
Table 1. Electrical properties of different coating materials: bare gold, DEX-loaded electrospun PLDL75G25A (PLGA) nanofibers on the electrodes (PLGA
NFs), alginate hydrogel coating of DEX-loaded electrospun PLGA NFs on the electrodes (HGþ PLGA NFs), cloudy PEDOT inside the alginate hydrogel on
the electrodes (HGþ PEDOT), PEDOT NTs on the electrodes (PEDOT NTs), PEDOT NTs and cloudy PEDOT inside the hydrogel on the electrodes
(PEDOT NTsþHGþPEDOT) [a].
Impedance [kV] CCD [mC cm2] Epc [V] Epa [V] Ipc [nA] Ipa [nA]
Bare gold 783.3 15 1.28 0.6 NA[b] NA NA NA
PLLA NFs 2246.7 23 NA NA NA NA NA
HGþ PLLA NFs 3472.4 19 NA NA NA NA NA
HGþ PEDOT 33.1 4 41.2 2.8 0.56 0.38 23.1 52.1
PEDOT NTs 10.7 2 112.4 9.1 0.48 0.59 62.4 126.7
PEDOT NTsþHGþ PEDOT 2.5 0.5 223.8 6.4 0.60 0.68 113.2 175.4
[a] PEDOT was electrochemically polymerized on the neural microelectrodes with an applied charge density of 2.88 C cm2. Data are shown for standard
deviation (n¼ 48). [b] NA¼ not available due to nonconductive coating layer.











580A threshold charge density (minimum) is required to generate
neural excitation however there is a limit for charge density
(maximum of 10mC cm2), which causes damage to neural
tissue.[57,58] According to Table 1, the CCD during one cycle of CV
(swept voltage between 0.9 and 0.5) for a 1 250-mm2 gold
electrode was 1.28 0.6 mC cm2. However, this value increased
to 41.2 2.8 mC cm2 for cloudy PEDOT inside hydrogel
(HGþPEDOT), 112.4 9.1 mC cm2 for PEDOT NTs, and
223.8 6.4 mC cm2 for a combination of PEDOT NTs and
cloudy PEDOT inside the hydrogel (PEDOT NTsþHGþPEDOT).
The electrodes of interest in this study were small diameter
microelectrodes (40mm) designed primarily for local neural
recording. However, given these dramatic changes in CCD found
with our materials, we expect that they will also prove to be
particularly important for large electrode stimulating devicesFigure 8. SEM images of electrospun PLDL75G25A nanofibers showing the d
days, no significant morphological changes were observed. B) After 15 days,
C) After 5weeks, only diffused fibers and of some piece of degraded materia
nanofibers during in vitro degradation. Data are shown for standard devia
 2009 WILEY-VCH Verlag GmbH &such as deep brain stimulators, pacemakers, and peripheral nerve
cuff electrodes.2.6. Weight Loss and Water Absorption of PLDL75G25A
The mechanism of degradation in poly (a-hydroxy acids) such as
PLLA and PLDL75G25A films and microstructures in aqueous
media has been widely investigated.[59–62] However, the degrada-
tion behavior of their nanofibers prepared by electrospinning has
been less studied.[63,64] Figure 8D shows the mass loss and water
uptake of electrospun PLDL75G25A nanofiber mat. The in vitro
degradation mechanism of water insoluble bioresorbable poly
(a-hydroxy acids) is hydrolytic degradation. This degradation
proceeds more rapidly in the center than at the surface as theegradation of nanofibers in PBS solution (pH¼ 7.4, T¼ 37 8C). A) After 6
the swollen fibers started diffusing and creating massive bulk of polymer.
ls were left. D) Percent weight loss and water absorption of PLDL75G25A
tion (n¼ 10).










www.afm-journal.dewater penetrate into the polymer.[65] In contrast to semi-
crystalline PLLA, PLDL75G25A is an amorphous polymer
allowing greater absorption of water into the polymer and faster
degradation.[66] During the first 6 days of incubation (this time
period was defined as the induction period), PLDL75G25A
exhibited a very slow weight loss rate. It was reported that once
poly(a-hydroxy acids) are placed in an aqueous medium, they
absorb water and hydrolytic cleavage of the ester bonds starts with
decreasingmolecular weight.[61] At this early stage, degradation is
occurring predominantly at the surface of the nanofibers rather
than in the bulk, because of the gradient in concentration of the
absorbed water.[67] The mass loss was accelerated after this period
because of even more ester bonds cleavage due to absorption of
water. About 30% of weight loss was observed within 2 weeks of
degradation (Fig. 8D). Since the swollen nanofibers began
diffusing together and creating a massive polymer (Fig. 8B and
C), the weight loss was decelerated after 2 weeks (Fig. 8D). Due to
the unique nanofiber morphology with extremely high surface
area to volume ratio, the electrospun PLDL75G25A nanofibermat
absorbed about 20wt % of water after 10 days of incubation. In
contrast, it took more than 2 weeks for poly (glycolic acid) (PGA)
solid films to achieve the same water absorption level.[68]
However, the water content increased dramatically after
15 days of degradation. For example, the water uptake reached
a 100wt % level of the initial sample weight after 35 days. It was
too difficult to measure the water absorption after day 35 because
of too much chain cleavage and loss of molecular weight of the
polymer. The corresponding mass loss after 35 days was more
than 90wt %, which was faster than that of the cast solid film.[69]
The water uptake could be attributed both to the formation of a
porous surface in the nonwovenmembrane and to the swelling of
degraded products. Figure 8B and C illustrates the morphological
changes of the electrospun PLDL75G25A nanofiber membrane
during in vitro degradation. No significant morphological
changes were observed in the first 6 days of incubation
(Fig. 8A). However, the swollen fibers started diffusing and
creating massive bulk of polymer after 15 days of degradation
(Fig. 8B). After 5 weeks of degradation, only diffused fibers and of
some piece of degraded materials were left (Fig. 8C).
2.7. Dexamethasone Release Profile
In this study, DEX as an anti-inflammatory drug was incorporated
in electrospun nanofibers. DEX, a synthetic corticosteroid is
widely used in treatment of neurological disease, especially to
reduce cerebral edema associated with tumors.[70] Because of its
limited ability to cross the blood–brain barrier, DEX needs to be
administered in high systemic dosages to achieve therapeutic
levels in the brain. However, systemic administration of DEX is
associated with serious side effects.[42,43] To accomplish this, we
first incorporated DEX within biodegradable nanofibers and
finally coated them with alginate hydrogel. Poly(esters) based on
poly(lactic acid), poly(glycolic acid), and their copolymers PLGA
have been widely used as biocompatible polymeric materials for
controlled drug delivery systems by the incorporation of drugs
into their polymer matrices.[45,49,51,71] This polymer protection
can involve delaying the dissolution of drug molecules and
controlling the rate of drug release via hydrolytic degradation ofAdv. Funct. Mater. 2009, 19, 573–585  2009 WILEY-VCH Verlthe polymer matrix. Figure 9 shows DEX release profiles from
PLLA, PLDLA, PLDL75G25A, and alginate-coated PLDL75G25A
nanofibers. PLLA is a high molecular weight semi-crystalline
polymer and formation of PLLA spun fibers increases the
crystallinity of PLLA.[72] In contrast, PLDLA and PLDL75G25A
are lower molecular weight and amorphous polymers. Since,
increasing the molecular weight and crystallinity causes a
decrease in the degradation rate, PLLA degrades significantly
slower than PLDLA and PLDL75G25A.[60–62,65,73,74] There was a
burst of about 6% during first week of incubation of PLLA in PBS
and only about 10% of DEX was released after 41 days (Fig. 9A).
Since PLDLA is more hydrophobic than PLDL75G25A, the DEX
release profile from PLDL75G25A is faster than PLDLA (Fig. 9B).
As illustrated in Figure 10A–C, a significant initial release of
accumulated drug on the surface of nanofibers (burst effect) due
to an initial surface erosion followed by a slow release of DEX was
observed for all polymers; this phenomenon has been frequently
reported.[75,76] The burst effect may be primarily caused by an
imperfect entrapment of the drug in the polymer matrix or their
tendency to migrate to the nanofiber surface during the
electrospinning process (Fig. 10A). As the nanofibers are placed
in an aqueous environment, at the initial stage water penetrates
into the surface and a large amount of DEX is released due to
the initial surface erosion (Fig. 10B). Subsequently, water
penetrates into the bulk of the nanofibers causing polymer bond
cleavage and bulk erosion, generating interconnecting pores and
channels within nanofibers that allow the remaining DEX to be
released (Fig. 10C).
As illustrated in Figure 1C, the DEX-loaded biodegradable
nanofibers of PLDL75G25A were covered by alginate hydrogel
on the surface of the neural electrode. Controlled release of
proteins and drugs from alginate hydrogel matrices has been
reported.[77–79] The release mechanism of drugs from hydrogels
such as alginate is diffusion controlled. This means the drugs
must diffuse within an aqueous solution through the tortuous
pathways of the hydrogel network in order to exit from the
matrix. Figure 9B and C show sustained release of DEX from
PLDL75G25A after coating with alginate hydrogel during 1 000 h
and 20 h of incubation in PBS solution, respectively. Since the
samples were dehydrated before placing in PBS solution, the
initial release of DEX was delayed about 4 h due to swelling and
water uptake of alginate (Fig. 9C). Also, the release burst effect
and release profile of DEX was reduced by about 40%. As shown
schematically in Figure 10D and E, the water insoluble DEX
molecules that are released from nanofibers need to diffuse
through the hydrophilic alginate matrix. Therefore, the trapped
DEX in alginate releases into the media slower than from the
nanofibers alone. In case of PLDL75G25A nanofibers, approxi-
mately 95% of DEX was released in 5 weeks whereas for the
entrapped PLDL75G25A nanofibers in alginate matrix, only 60%
of DEX was released after 5 weeks (Fig. 9B). The advantage of
composite hydrogel-biodegradable polymer coatings is that there
can be a more prolonged and sustained release of drug due to the
two mechanisms of release: delayed dissolution of the nanofibers
and diffusion through the hydrogel. This makes it possible to
control the delivery of the DEX without a burst effect. At the
beginning, the drug will be released into the hydrogel matrix due
to degradation of PLDL75G25A nanofibers, followed by slower











Figure 9. Percentage cumulative mass release profiles of DEX-loaded
A) PLLA nanofibers (black squares) over a time span of 1000 h, B) PLDLA
nanofibers (blue hollow circles), PLDL74G25A nanofibers (black squares),
and alginate hydrogel-coated PLDL74G25A nanofibers (red circles), over
1000 h, C) a zoom window of (B) for PLDL74G25A nanofibers (black
squares), and alginate hydrogel-coated PLDL74G25A nanofibers (red
circles), over 20 h. Data are shown for standard deviation (n¼ 20).
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We have established methods for the fabrication of multi-
functional nanobiomaterials that can be used for coating neural
microelectrode arrays. The process includes electrospinning of
DEX-incorporated biodegradable nanofibers, encapsulation of
these nanofibers by an alginate hydrogel layer, and then
electrochemical polymerization of the conducting polymer
PEDOTon the electrode site, around the DEX-loaded nanofibers,
and within the hydrogel matrix. We have shown that electrical
properties of neural microelectrodes have been significantly
improved with these coatings. The impedance of the electrode
sites significantly decreased, especially at 1 kHz from 783 15.7
to 2.5 0.5 kV (about two orders of magnitude). The CCDFigure 10. Schematic illustration showing proposed mechanism of DEX
release and degree of degradation of electrospun nanofibers. A) DEX-
loaded electrospun nanofibers showing accumulation of drug molecules at
the surface of nanofibers before placing in aqueous solution (t¼ t0),
a) cross-section of nanofibers with surface area Aa, B) fast release of
DEX from surface of nanofibers (burst effect) after placing in aqueous
solution (t1> t0) due to initial surface erosion of nanofibers, b) cross-
section of nanofibers with surface area Ab (Aa>Ab). C) Slow release of drug
due to bulk erosion or delayed dissolution mechanism at t2 t1, c) cross-
section of nanofibers with surface area Ac, D) alginate hydrogel coating of
DEX-loaded electrospun nanofibers shown in (A) before placing in aqueous
solution (t¼ t0), d) cross-section of nanofibers with surface area Ad
(Ad¼Aa), E) sustained release of drug from alginate hydrogel using
delayed dissolution and diffusion mechanism at t1 t0, e) cross-section
of nanofibers with surface area Ae (Ae<Ac) due to slower degradation of
nanofibers.
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The surface morphology and degradation rate of PLDL75G25A
has been studied and the release profile of DEX from PLLA,
PLDLA, and PLDL75G25A has been investigated. It has been
demonstrated that alginate hydrogel coatings could not only
decrease the burst effect of DEX release for controlling the long-
term release patterns but also create a matrix for growing PEDOT
within the alginate in order to increase the conductivity of
electrode sites. This method provides a generally useful means
for creating soft, low impedance, high charge density, controlled
releasing for neural prostheses, and other biosensor applications.4. Experimental
Materials: High molecular weight PLLA (RESOMER L 210) with
inherent viscosity 3.3–4.3 dl g1 was purchased from Boehringer Ingelheim
Pharma GmbH and Co. (KG, Germany). PLDL75G25A (Medisorb 7525 DL,
low I.V., inherent viscosity 0.6–0.7 dl g1, MW 92 kDa) and PLDLA
(Medisorb 100 DL, low I.V., inherent viscosity 0.7–0.8 dl g1, MW 100 kDa)
was obtained from Alkermes Inc. (Cincinnati, Ohio). DEX (MW 392.5 g
mol1) was purchased from Alexis Corporation. 3,4-ethylenedioxythio-
phene (EDOT, BAYTRON M) with molecular weight 142.17 g mol1 was
received fromH. C. Starck Inc. (Newton,MA). Lithiumperchlorate (LiClO4)
was purchased and used as received from Aldrich. Sodium alginate (MVG)
was purchased from Pronova Biomedical (Norway) with an overall
guluronic acid (G-block) content of approximately 60%, as reported by the
manufacturer. Sterile phosphate buffered saline (PBS) was purchased from
Hyclone (cell culture media, 0.1mm sterile filtered).
Fabrication of Electrospun Nanofiber Templates: PLLA, PLDLA, and
PLDL75G25A nanofibers loaded with DEX were prepared by electrospin-
ning of polymer/drug solutions. PLLA/DEX solution was prepared by
dissolving a mixture of PLLA (0.4 g) and DEX (0.1 g) in chloroform (6.4mL)
at a temperature of 50 8C for 10 h in order to have a homogenous solution
with PLLA concentration of 3.96% (w/w), DEX concentration of 0.99%, and
ratio of PLLA/DEX:4:1. In case of PLDL75G25A and PLDLA, a mixture of
polymer (1.7 g) and DEX (0.17 g) was added to chloroform (6.4mL) then
the solution was stirred at a temperature of 55 8C for 10 h to prepare a
homogeneous solution with concentration of 14.82% w/w polymer and
1.48% w/w DEX and ratio of polymer/DEX:10:1. DEX-loaded nanofibers
were directly deposited on the microfabricated electrode arrays by
electrospinning (Fig. 2). The electrospinning process was carried out in
an electrical field of 0.6 kV cm1 with flow rate of 0.25mL h1 for 1min.
The neural probes were held at a distance of 11 cm from the syringe
needle.
Preparation of Alginate Coating: An aqueous alginate solution was
prepared by dissolvingMVG in deionized water. The alginate concentration
in the solution was 1% w/w. Hydrogel coating was then formed around the
electrode shank by dipping the shank sequentially in both alginate solution
and CaCl2 (0.1 M) solution. The hydrogel was dried by exchanging the water
in the gel by ethanol followed by drying in an air stream.
Electrochemical Deposition of Conducting Polymers: The electrochemical
deposition was performed on an individual electrode site of the eight-
channel acute neural electrode with 1 250-mm2 gold recording sites by an
Autolab PGSTAT-12 (EcoChemie, Utrecht, Netherlands) in galvanostatic
mode with a conventional two-electrode configuration at room tempera-
ture. Conducting polymer deposition was carried out in EDOT (0.01M) and
M LiClO4 (0.1 M) aqueous solution at a current density of 0.5mA cm
2 for
30min. The amount of polymer coated on the electrode site was controlled
by the total charge passed during polymerization. The working electrode
was connected to the electrode site. The reference and counter electrodes
were connected to a platinum wire within the EDOT/LiClO4 solution.
PEDOT was polymerized on total 144 electrode sites for each of the
following samples: i) alginate hydrogel-coated electrode (HGþPEDOT)
(Fig. 7D), ii) electrospun nanofibers (PEDOT NTs) (Fig. 7E),Adv. Funct. Mater. 2009, 19, 573–585  2009 WILEY-VCH Verliii) electrospun nanofibers and alginate hydrogel-coated electrode (PEDOT
NTsþHGþPEDOT) (Fig. 7F).
Dissolving Alginate Hydrogel and Electrospun Nanofibers for SEM: To
dissolve the alginate hydrogel layer, neural electrodes were immersed into
deionized water for 24 h. Afterward they were placed into chloroform for
1min to remove the electrospun nanofibers.
Electrochemical Impedance Spectroscopy: An Autolab PGSTAT-12 and
Frequency Response Analyzer (FRA) software were used to record
impedance spectra of electrode sites. A solution of 0.1 M PBS (pH¼ 7)
was used as an electrolyte in a three-electrode cell. The working electrode
was connected to electrode site through a connector. The counter electrode
was connected to a platinum foil that was placed in a glass container. An
Ag/AgCl reference electrode and the neural microelectrode tip were
immersed in glass container of electrolyte. An AC sinusoidal signal of 5mV
in amplitude was used to record the impedance over a frequency range of
1–105Hz.
Cyclic Voltammetry (CV): CV was performed using an Autolab PGSTAT-
12 instrument in a three-electrode configuration as described earlier. A scan
rate of 100mV s1 was used and the potential on the working electrode was
swept between 0.9 and 0.5 V. All the potentials are reported versus the
Ag/AgCl reference electrode. Before each CV curve was recorded, several
cycles were swept to insure that the PEDOT had reached a stable state. The
GPES software (EcoChemie, Utrecht, Netherlands) was used to estimate
the total CCD during one cycle of CV.
Degradation Studies: Electrospun fiber mats were cut into a total of ten
rectangular shapes with dimensions of 202030 mm3 for in vitro
degradation studies. The electrospun specimens were dipped into 70%
ethanol for 20 s to minimize the potential for bacterial contamination and
placed into sterile, closed bottles containing sterile PBS (100mL) (pH
7.27), and incubated in vitro at a temperature of 37.0 0.7 8C for different
periods of time. For the in vitro degradation study, four specimens
were recovered at the end of each degradation period and dabbed dry with a
tissue, and each sample was weighed immediately (Ww). The samples were
then dried in a vacuum oven at room temperatures for 1week and were
weighed again (Wd). The mass loss and the water content percentages of
the samples were calculated with the following equations, based on the
initial mass of each sample (W0) before incubation:
mass loss% ¼ ðWd W0Þ
W0
 100 ð1Þ
water content% ¼ ðWw WdÞ
W0
 100 ð2Þ
In Vitro Drug Release Study: The release of DEX from PLLA, PLDLA,
and PLDL75G25A nanofibers was monitored as a function of incubation
time in PBS at 37 8C. The samples were immersed in PBS solution
(pH¼ 7.4). At specific times the concentration of DEX was determined in
the solution by a DU UV/Vis Spectrophotometer (Beckman Coulter Inc.) at
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